Last reviewed · How we verify
Concomitant treatment
Concomitant treatment refers to the simultaneous administration of multiple therapeutic agents to enhance efficacy or address multiple disease pathways.
At a glance
| Generic name | Concomitant treatment |
|---|---|
| Sponsor | R-Pharm International, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Concomitant treatment is a therapeutic strategy rather than a single drug entity, involving the coordinated use of two or more medications to achieve synergistic effects, improve outcomes, or manage multiple aspects of a disease. The specific mechanism depends entirely on the individual drugs being combined and their respective targets.
Approved indications
Common side effects
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma (PHASE1)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay (NA)
- Use of Augmented Reality Glasses and Noise-Cancelling Headphones to Reduce Dental Anxiety in Adult Patients (NA)
- Prevent TB: Choice Architecture for TPT Delivery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Concomitant treatment CI brief — competitive landscape report
- Concomitant treatment updates RSS · CI watch RSS
- R-Pharm International, LLC portfolio CI